1-7 of 7
Peter Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Aintzane Zabaleta, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Jesús San Miguel, Bruno Paiva, Esperanza Martín-Sánchez
Journal: Blood
Blood (2023) 142 (Supplement 1): 1921.
https://doi.org/10.1182/blood-2023-182150
Published: 2023
Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Aintzane Zabaleta, Esperanza Martín-Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus San-Miguel, David Martinez-Cuadron, Pau Montesinos, Bruno Paiva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4178.
https://doi.org/10.1182/blood-2023-184797
Published: 2023
Journal Articles

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

Aurélie Dupuy, Laura Pelletier, Jerome Giustiniani, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Corinne Haioun, Philippe Gaulard, Nicolas Ortonne
Journal: Blood
Blood (2023) 142 (Supplement 1): 4384.
https://doi.org/10.1182/blood-2023-189088
Published: 2023
Journal Articles

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou
Journal: Blood
Blood (2022) 140 (Supplement 1): 7097–7099.
https://doi.org/10.1182/blood-2022-169072
Published: 2022
Journal Articles

Effect of Pulmonary Hypertension and Other Cardiovascular Diseases in Overall Prognosis of Patients with Myelofibrosis

Juan Lopez-Mattei, MD, Srdan Verstovsek, MD PhD, Cezar Iliescu, MD, Karan Bhatti, MD, Nicolas Palaskas, MD, Peter Kim, MD, Bryan Gray, D.O., Saadia Faiz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4310.
https://doi.org/10.1182/blood-2018-99-118900
Published: 2018
Journal Articles

Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)

Christopher Gurguis, MS, Lizette Rodriguez de Armas, Hagop M. Kantarjian, MD, Prajwal C Boddu, MD, Preetesh Jain, MBBS,MDDM,PhD, Gautam Borthakur, MD, Dana Elena Giza, Gloria Iliescu, MD, Juan Lopez-Mattei, Peter Kim, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, William G Wierda, MD PhD, Steven Kornblau, MD, Elias J. Jabbour, MD, Cezar Iliescu, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2893.
https://doi.org/10.1182/blood.V130.Suppl_1.2893.2893
Published: 2017
Journal Articles

Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.

Peter Kim, Gitte Gerhard, Troy O. Harasym, PhD, Wahseng Lim, PhD, Natalia Zisman, Lawrence D Mayer, PhD, Donna E. Hogge, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2071.
https://doi.org/10.1182/blood.V114.22.2071.2071
Published: 2009